Page last updated: 2024-12-11
trans-3-methyl-2-hexenoic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
trans-3-methyl-2-hexenoic acid: schizophrenic odor factor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(2E)-3-methylhex-2-enoic acid : A monounsaturated fatty acid that is (2E)-hexenoic acid in which the hydrogen at position 3 has been replaced by a methyl group. A malodourous component in the sweat of schizophrenics. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6443739 |
| CHEBI ID | 144845 |
| SCHEMBL ID | 195384 |
| MeSH ID | M0045983 |
Synonyms (32)
| Synonym |
|---|
| 3-methyl-2-hexenoic acid |
| 3-methyl-2e-hexenoic acid |
| LMFA01030793 |
| CHEBI:144845 |
| 27960-21-0 |
| trans-3-methyl-2-hexenoic acid |
| (2e)-3-methylhex-2-enoic acid |
| (e)-3-methylhex-2-enoic acid |
| 3-methylhex-2-enoic acid |
| 35205-70-0 |
| EN300-55079 |
| 2-hexenoic acid, 3-methyl-, (e)- |
| q98fu4wj65 , |
| unii-q98fu4wj65 |
| tmha |
| AKOS008113312 |
| 3-methyl-2-hexenoic acid, (2e)- |
| SCHEMBL195384 |
| (2e)-3-methyl-2-hexenoic acid |
| e-3-methyl-2-hexenoic acid |
| A1-01430 |
| (e)-3-methyl-2-hexenoic acid |
| mfcd02258698 |
| AS-58087 |
| A901718 |
| F8880-7277 |
| Q3487540 |
| CS-0072967 |
| EN300-398557 |
| A901147 |
| DTXSID701020850 |
| Z352746820 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (3)
| Class | Description |
|---|---|
| short-chain fatty acid | An aliphatic monocarboxylic acid with a chain length of less than C6. If any non-hydrocarbon substituent is present, the compound is not normally regarded as a short-chain fatty acid. |
| monounsaturated fatty acid | Any fatty acid with one double or triple bond in the fatty acid chain and singly bonded carbon atoms in the rest of the chain. MUFAs have positive effects on the cardiovascular system, and in diabetes treatment. |
| alpha,beta-unsaturated monocarboxylic acid | A monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||